In a related presentation at the AACR Annual Meeting,1 the antibody-drug conjugate DMUC5754A showed encouraging activity in women with ovarian cancer, particularly those with platinum-resistant disease, which currently lacks effective treatment options. The first-in-human phase I study included 44 patients with advanced, recurrent, platinum-resistant ovarian cancer. Of these difficult-to-treat patients, one achieved a complete response and four achieved partial responses.
Results of the phase I study were reported at a press conference by Joyce F. Liu, MD, MPH, Instructor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School in Boston.
Mechanism of Action
DMUC5754A consists of an antibody linked to a highly potent antimitotic toxin called MMAE. The antibody is targeted to the MUC16 protein expressed in ovarian cancers and releases the toxin with relative selectivity to the MUC16-positive cancer cells, which are expressed in 80% of patients with ovarian cancer. All five confirmed responses occurred in patients with high expression levels of MUC16 in their cancer cells, at the maximum tolerated dose of 2.4 mk/kg.
Dr. Liu explained that although chemotherapy and surgery are initially effective in the treatment of ovarian cancer, most patients will experience a recurrence, and platinum-resistant patients are challenging to treat, with limited therapeutic options.
The novel agent had tolerable safety, with fatigue as the most common grade 3 adverse event. Peripheral neuropathy was also reported but was manageable and reversible with dose adjustments.
“This is the first study of an antibody-drug conjugate in ovarian cancer. If the encouraging activity is confirmed in future studies, this would represent a real step forward in identifying new, effective treatments for a type of ovarian cancer that is difficult to treat,” Dr. Liu told listeners. Further trials evaluating DMUC5754A in advanced ovarian cancer are being planned. ■
Disclosure: Dr. Liu reported no potential conflicts of interest.
1. Liu J, Moore K, Birrer M, et al: Targeting MUC16 with the antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics. AACR Annual Meeting. Abstract LB-290. Presented April 9, 2013.
A biomarker analysis of the pivotal EMILIA trial suggests that women with metastatic HER2-positive breast cancer with tumors that have high expression of HER2 derive the most robust benefit from treatment with the antibody-drug conjugate T-DM1 (also now known as ado-trastuzumab emtansine...
Commenting on both Dr. Baselga’s study in breast cancer and Dr. Liu’s study in ovarian cancer at the AACR press conference, Louis M. Weiner, MD, Director of the Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, said that antibody-drug conjugates “represent the fulfillment...